Targeted therapies in the treatment of adult acute myeloid leukemias: current status and future perspectives.
作者： Germana Castelli , Elvira Pelosi , Ugo Testa
关键词:
摘要: The rapid advancement of next-generation sequencing techniques and the identification molecular driver events responsible for leukemia development are opening door to new pharmacologic-targeted agents tailor treatment acute myeloid (AML) in individual patients. However, use targeted therapies AML has met with only modest success. Molecular studies have identified subsets characterized by mutational events, such as NPM1, FLT3–ITD IDH1–2 mutations, provided preclinical evidence that targeting these mutant molecules could represent a valuable therapeutic strategy. Recent first pieces FLT3 FLT3-mutant AMLs, IDH1/2 inhibition IDH-mutant AMLs membrane preferentially expressed on leukemic progenitor/stem cells, CD33 CD123, clinically
futuremedicine.com 
sci-hub.se 参考文章(90)
Katharine Yen, Fang Wang, Jeremy Travins, Yue Chen, Hua Yang, Kim Straley, Sung Choe, Marion Dorsch, David P. Schenkein, Samuel Agresta, Scott Biller, Michael Su, AG-221 Offers a Survival Advantage In a Primary Human IDH2 Mutant AML Xenograft Model Blood. ,vol. 122, pp. 240- 240 ,(2013) , 10.1182/BLOOD.V122.21.240.240
Marina Konopleva, Daniel A. Pollyea, Jalaja Potluri, Brenda J. Chyla, Todd Busman, Evelyn McKeegan, Ahmed Salem, Ming Zhu, Justin L. Ricker, William Blum, Courtney D. DiNardo, Martin Dunbar, Rachel Kirby, Nancy Falotico, Joel D. Leverson, Rod A. Humerickhouse, Mack Mabry, Richard M. Stone, Hagop M. Kantarjian, Anthony G. Letai, A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML) Blood. ,vol. 124, pp. 118- 118 ,(2014) , 10.1182/BLOOD.V124.21.118.118
Elvira Pelosi, Germana Castelli, Ugo Testa, Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells. Blood Cells Molecules and Diseases. ,vol. 55, pp. 336- 346 ,(2015) , 10.1016/J.BCMD.2015.07.015
Cancer Genome Atlas Research Network, None, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia The New England Journal of Medicine. ,vol. 368, pp. 2059- 2074 ,(2013) , 10.1056/NEJMOA1301689
Peter Hokland, Hans B. Ommen, Matthew P. Mulé, Christopher S. Hourigan, Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia Seminars in Hematology. ,vol. 52, pp. 184- 192 ,(2015) , 10.1053/J.SEMINHEMATOL.2015.04.001
Hervé Dombret, John F. Seymour, Aleksandra Butrym, Agnieszka Wierzbowska, Dominik Selleslag, Jun Ho Jang, Rajat Kumar, James Cavenagh, Andre C. Schuh, Anna Candoni, Christian Récher, Irwindeep Sandhu, Teresa Bernal del Castillo, Haifa Kathrin Al-Ali, Giovanni Martinelli, Jose Falantes, Richard Noppeney, Richard M. Stone, Mark D. Minden, Heidi McIntyre, Steve Songer, Lela M. Lucy, C. L. Beach, Hartmut Döhner, International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts Blood. ,vol. 126, pp. 291- 299 ,(2015) , 10.1182/BLOOD-2015-01-621664
E. M. Lee, D. Yee, S. J. Busfield, J. F. McManus, N. Cummings, G. Vairo, A. Wei, H. S. Ramshaw, J. A. Powell, A. F. Lopez, I. D. Lewis, M. N. McCall, R. B. Lock, Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice Haematologica. ,vol. 100, pp. 914- 926 ,(2015) , 10.3324/HAEMATOL.2014.113092
Ujunwa C Okoye-Okafor, Boris Bartholdy, Jessy Cartier, Enoch N Gao, Beth Pietrak, Alan R Rendina, Cynthia Rominger, Chad Quinn, Angela Smallwood, Kenneth J Wiggall, Alexander J Reif, Stanley J Schmidt, Hongwei Qi, Huizhen Zhao, Gerard Joberty, Maria Faelth-Savitski, Marcus Bantscheff, Gerard Drewes, Chaya Duraiswami, Pat Brady, Arthur Groy, Swathi-Rao Narayanagari, Iléana Antony-Debre, Kelly Mitchell, Heng Rui Wang, Yun-Ruei Kao, Maximilian Christopeit, Luis Carvajal, Laura Barreyro, Elisabeth Paietta, Hideki Makishima, Britta Will, Nestor Concha, Nicholas D Adams, Benjamin Schwartz, Michael T McCabe, Jaroslav Maciejewski, Amit Verma, Ulrich Steidl, New IDH1 mutant inhibitors for treatment of acute myeloid leukemia Nature Chemical Biology. ,vol. 11, pp. 878- 886 ,(2015) , 10.1038/NCHEMBIO.1930
Maria Paola Martelli, Ilaria Gionfriddo, Federica Mezzasoma, Francesca Milano, Sara Pierangeli, Floriana Mulas, Roberta Pacini, Alessia Tabarrini, Valentina Pettirossi, Roberta Rossi, Calogero Vetro, Lorenzo Brunetti, Paolo Sportoletti, Enrico Tiacci, Francesco Di Raimondo, Brunangelo Falini, Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells Blood. ,vol. 125, pp. 3455- 3465 ,(2015) , 10.1182/BLOOD-2014-11-611459
Sha Yi, Lu Wen, Jing He, Youping Wang, Fei Zhao, Jie Zhao, Zichu Zhao, Guohui Cui, Yan Chen, Deguelin, a selective silencer of the NPM1 mutant, potentiates apoptosis and induces differentiation in AML cells carrying the NPM1 mutation. Annals of Hematology. ,vol. 94, pp. 201- 210 ,(2015) , 10.1007/S00277-014-2206-X